Serveur d'exploration H2N2

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
***** Acces problem to record *****\

Identifieur interne : 000415 ( Pmc/Corpus ); précédent : 0004149; suivant : 0004160 ***** probable Xml problem with record *****

Links to Exploration step


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice.</title>
<author>
<name sortKey="Kulkarni, A B" sort="Kulkarni, A B" uniqKey="Kulkarni A" first="A B" last="Kulkarni">A B Kulkarni</name>
</author>
<author>
<name sortKey="Connors, M" sort="Connors, M" uniqKey="Connors M" first="M" last="Connors">M. Connors</name>
</author>
<author>
<name sortKey="Firestone, C Y" sort="Firestone, C Y" uniqKey="Firestone C" first="C Y" last="Firestone">C Y Firestone</name>
</author>
<author>
<name sortKey="Morse, H C" sort="Morse, H C" uniqKey="Morse H" first="H C" last="Morse">H C Morse</name>
</author>
<author>
<name sortKey="Murphy, B R" sort="Murphy, B R" uniqKey="Murphy B" first="B R" last="Murphy">B R Murphy</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">8419638</idno>
<idno type="pmc">237459</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC237459</idno>
<idno type="RBID">PMC:237459</idno>
<date when="1993">1993</date>
<idno type="wicri:Area/Pmc/Corpus">000415</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000415</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice.</title>
<author>
<name sortKey="Kulkarni, A B" sort="Kulkarni, A B" uniqKey="Kulkarni A" first="A B" last="Kulkarni">A B Kulkarni</name>
</author>
<author>
<name sortKey="Connors, M" sort="Connors, M" uniqKey="Connors M" first="M" last="Connors">M. Connors</name>
</author>
<author>
<name sortKey="Firestone, C Y" sort="Firestone, C Y" uniqKey="Firestone C" first="C Y" last="Firestone">C Y Firestone</name>
</author>
<author>
<name sortKey="Morse, H C" sort="Morse, H C" uniqKey="Morse H" first="H C" last="Morse">H C Morse</name>
</author>
<author>
<name sortKey="Murphy, B R" sort="Murphy, B R" uniqKey="Murphy B" first="B R" last="Murphy">B R Murphy</name>
</author>
</analytic>
<series>
<title level="j">Journal of Virology</title>
<idno type="ISSN">0022-538X</idno>
<idno type="eISSN">1098-5514</idno>
<imprint>
<date when="1993">1993</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>Previous studies demonstrated that the pulmonary resistance to respiratory syncytial virus (RSV) challenge induced by immunization with a recombinant vaccinia virus expressing the M2 protein of RSV (vac-M2) was significantly greater 9 days after immunization than at 28 days and was mediated predominantly by CD8+ T cells. In this study, we have extended these findings and sought to determine whether the level of CD8+ cytotoxic T-lymphocyte (CTL) activity measured in vitro correlates with the resistance to RSV challenge in vivo. Three lines of evidence documented an association between the presence of pulmonary CTL activity and resistance to RSV challenge. First, vac-M2 immunization induced pulmonary CD8+ CTL activity and pulmonary resistance to RSV infection in BALB/c (H-2d) mice, whereas significant levels of pulmonary CTL activity and resistance to RSV infection were not seen in BALB.K (H-2k) or BALB.B (H-2b) mice. Second, pulmonary CD8+ CTL activity was not induced by infection with other vaccinia virus-RSV recombinants that did not induce resistance to RSV challenge. Third, the peak of pulmonary CTL activity correlated with the peak of resistance to RSV replication (day 6), with little resistance being observed 45 days after immunization. An accelerated clearance of virus was not observed when mice were challenged with RSV 45 days after immunization with vac-M2. The results indicate that resistance to RSV induced by immunization with vac-M2 is mainly mediated by primary pulmonary CTLs and that this resistance decreases to very low levels within 2 months following immunization. The implications for inclusion of CTL epitopes into RSV vaccines are discussed in the context of these observations.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article">
<pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Virol</journal-id>
<journal-title>Journal of Virology</journal-title>
<issn pub-type="ppub">0022-538X</issn>
<issn pub-type="epub">1098-5514</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">8419638</article-id>
<article-id pub-id-type="pmc">237459</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice.</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kulkarni</surname>
<given-names>A B</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Connors</surname>
<given-names>M</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Firestone</surname>
<given-names>C Y</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morse</surname>
<given-names>H C</given-names>
<suffix>3rd</suffix>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Murphy</surname>
<given-names>B R</given-names>
</name>
</contrib>
</contrib-group>
<aff>Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.</aff>
<pub-date pub-type="ppub">
<month>2</month>
<year>1993</year>
</pub-date>
<volume>67</volume>
<issue>2</issue>
<fpage>1044</fpage>
<lpage>1049</lpage>
<abstract>
<p>Previous studies demonstrated that the pulmonary resistance to respiratory syncytial virus (RSV) challenge induced by immunization with a recombinant vaccinia virus expressing the M2 protein of RSV (vac-M2) was significantly greater 9 days after immunization than at 28 days and was mediated predominantly by CD8+ T cells. In this study, we have extended these findings and sought to determine whether the level of CD8+ cytotoxic T-lymphocyte (CTL) activity measured in vitro correlates with the resistance to RSV challenge in vivo. Three lines of evidence documented an association between the presence of pulmonary CTL activity and resistance to RSV challenge. First, vac-M2 immunization induced pulmonary CD8+ CTL activity and pulmonary resistance to RSV infection in BALB/c (H-2d) mice, whereas significant levels of pulmonary CTL activity and resistance to RSV infection were not seen in BALB.K (H-2k) or BALB.B (H-2b) mice. Second, pulmonary CD8+ CTL activity was not induced by infection with other vaccinia virus-RSV recombinants that did not induce resistance to RSV challenge. Third, the peak of pulmonary CTL activity correlated with the peak of resistance to RSV replication (day 6), with little resistance being observed 45 days after immunization. An accelerated clearance of virus was not observed when mice were challenged with RSV 45 days after immunization with vac-M2. The results indicate that resistance to RSV induced by immunization with vac-M2 is mainly mediated by primary pulmonary CTLs and that this resistance decreases to very low levels within 2 months following immunization. The implications for inclusion of CTL epitopes into RSV vaccines are discussed in the context of these observations.</p>
</abstract>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000415  | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000415  | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     
   |texte=   
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021